pancreatic cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The inclusion criteria of patients with malignant pancreatic tumors were as follows: 1.Patients diagnosed with pancreatic tumors based on pathological diagnosis (biopsy pathology or surgical pathology); Pancreatic tumors mainly included pancreatic ductal adenocarcinoma, mucous adenocarcinoma, acinar cell carcinoma and other malignant pathological types; IPMN/MCN with malignancy. 2.Signed an informed consent form. The inclusion criteria of high-risk groups of pancreatic cancer in this subject are 1. Patients with history of pancreatitis or suffering from pancreatitis; 2.Patients with potentially malignant pancreatic space occupation, including pancreatic mucinous cystic tumor (MCN) and intraductal papillary myxoma of pancreas (IPMN); 3. New-onset diabetes (NOD); 4.Persistent or progressive elevation of tumor markers such as CA19-9, CEA and CA12-5; 5.Patients with unexplained weight loss; 6.Patients with a family history of pancreatic cancer, immediate family members with pancreatic cancer; 7.Hereditary syndromes associated with pancreatic cancer, including HBOCS, CNC, FAP, HDGC, JPS, CMM, HPRCC, and Lynch syndromes; 8.Other patients considered to be at high risk for pancreatic cancer; 9.Signed an informed consent form. The recruitment criteria of control people were as follows: 1. Patients undergoing pancreatic surgery with non-pancreatic malignancies (including pNET, SCA, etc.); Or patients undergoing surgery for non-pancreatic disease (such as elective cholecystectomy); Or healthy people (who do not meet any of the high-risk group inclusion criteria and have no history of pancreatic related diseases); 2.Signed an informed consent form
Exclusion criteria
Exclusion criteria: 1.Pregnant woman 2.Infection with hepatitis B, hepatitis C, syphilis, HIV 3.Non-guardian young or elderly patients and can not take care of themselves, have serious mental disorders or mental abnormalities or other circumstances can not sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Genome;Quantitative detection of miRNA;Epigenomics;Proteome; | — |
Countries
China
Contacts
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College